Medical Doctor Program year 2025 Reported 2020–2025 Source: CMS Open Payments, 2026 publication

Samir Derisavifard

Urogynecology and Reconstructive Pelvic Surgery Rego Park, NY Medical Doctor

NPI 1477997690 CMS profile 8794694

9225 Queens Blvd Fl 2, Rego Park, NY 11374

Open in the dashboard

General payments

$5,693

49 records reported · program years 2020–2025

Research payments

$0

Paid to them · None reported · program years 2020–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Samir Derisavifard of Rego Park, NY is reported in the CMS Open Payments database as having received $5,693 across 49 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 44th percentile of Urogynecology and Reconstructive Pelvic Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $3,858 7
2024 General $388 8
2023 General $497 8
2022 General $176 8
2021 General $315 11
2020 General $459 7

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Samir Derisavifard
  • Urogynecology and Reconstructive Pelvic Surgery median
  • Middle half of Urogynecology and Reconstructive Pelvic Surgery
  • National median

In program year 2025, general payments to Samir Derisavifard were reported at $3,858. Among 149 Urogynecology and Reconstructive Pelvic Surgery profiles paid that year, the median was $779 and the middle half received between $301 and $2,705.

Show as a table
Year Samir Derisavifard Urogynecology and Reconstructive Pelvic Surgery median Middle half National median
2019 $0 $799 $319–$2,013 $163
2020 $459 $384 $158–$1,360 $114
2021 $315 $641 $247–$2,515 $132
2022 $176 $843 $347–$2,794 $149
2023 $497 $819 $308–$2,302 $160
2024 $388 $882 $306–$2,459 $164
2025 $3,858 $779 $301–$2,705 $169

Breakdown

Who paid General payments · program years 2020–2025
  1. FEMSelect Inc. $3,927 10 payments
  2. Medtronic, Inc. $643 10 payments
  3. Medtronic USA, Inc. $255 2 payments
  4. Axonics Modulation Technologies, Inc. $237 8 payments
  5. Boston Scientific Corporation $190 8 payments
  6. Olympus America Inc. $150 2 payments
  7. Coloplast Corp $131 1 payment
  8. Urovant Sciences Inc $45 2 payments
  9. Astellas Pharma US Inc $28 2 payments
  10. Valencia Technologies Corporation $27 1 payment
  11. Other $61 3 payments

Every payment, record by record

What the payments were for General payments · program years 2020–2025
  1. Consulting Fee $3,500 1 payment
  2. Food and Beverage $2,169 47 payments
  3. Gift $24 1 payment
Products named General payments · program years 2020–2025
  1. ENPLACE $3,927 10 payments
  2. INTERSTIM Sacral Nerve Stimulation $643 10 payments
  3. INTERSTIM Sacral Nerve Stimulation $255 2 payments
  4. Axonics $147 5 payments
  5. Bulkamid $140 3 payments
  6. iTIND System $138 1 payment
  7. ALTIS $131 1 payment
  8. Axonics r-SNM System $58 3 payments
  9. GEMTESA $45 2 payments
  10. GENERAL - PELVIC ORGAN PROLAPSE $44 2 payments
  11. Other $212 12 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 13 drugs

Part D claims

764

Median for Urology: 1,053

Drug cost

$123,175

Median for Urology: $101,464

Branded share of claims

45.9%

Median for Urology: 27.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Myrbetriq Mirabegron Brand 134 $63,294
Gemtesa Vibegron Brand 78 $42,506
Estradiol Generic 120 $7,852
Mirabegron Er Mirabegron Brand 11 $3,605
Tamsulosin Hcl Generic 190 $1,862
Trospium Chloride Er Trospium Chloride Brand 15 $1,664
Oxybutynin Chloride Er Oxybutynin Chloride Brand 78 $1,114
Solifenacin Succinate Generic 30 $692
Finasteride Generic 43 $313
Alfuzosin Hcl Er Alfuzosin Hcl Brand 11 $182

The 10 drugs with the highest cost, of 13 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 10,221 Part D prescribers listed as Urology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 54 billing codes

Paid by Medicare

$110,229

Of which drugs: $12,366

Medicare patients

261

Average age 76

Services billed

3,636

134 women, 127 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 56%
Diabetes 50%
Ischemic heart disease 41%
Depression 33%
Chronic kidney disease 32%
Heart failure 27%
Atrial fibrillation 26%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, onabotulinumtoxina, 1 unit J0585 Office 16 2,400 $11,969

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

49 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Urogynecology and Reconstructive Pelvic Surgery in New York

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record